newsfilter
← Latest News
Business Wire·

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

  • Xeris Biopharma Holdings will release its first quarter 2026 financial results before the U.S. market open on Thursday, May 7, 2026.
  • Management will host a conference call & webcast at 8:30 a.m. ET on May 7, 2026, to discuss financial & operational results.
  • Interested parties may pre-register via the investor relations website or the "Events" section, with registration recommended 15 minutes prior to the event.
  • The webcast, replay, & event information are accessible at https://xerispharma.com/investor-relations.
  • Xeris currently markets three products: Recorlev for endogenous Cushing's syndrome, Gvoke for severe hypoglycemia, & Keveyis for primary periodic paralysis.
  • The company's development pipeline is led by XP-8121, a Phase 3-ready once-weekly subcutaneous injection for hypothyroidism, alongside early-stage programs utilizing XeriSol & XeriJect platforms.
  • Xeris is headquartered in Chicago, IL, with investor inquiries directed to Senior Vice President Allison Wey at awey@xerispharma.com.